<DOC>
	<DOCNO>NCT00728910</DOCNO>
	<brief_summary>The investigator propose investigate use combination medication may improve cholesterol give additional benefit gain statin medication , Lipitor . It recommend patient meet certain criterion risk heart disease take statin medication improve cholesterol hopefully reduce risk heart disease . The combination therapy include Lipitor , Niaspan , investigational medication ( know ABT335 ) class drug call fibrates . We look see three medication together might improve risk factor atherosclerosis influence HDL cholesterol . The study also look safety side effect might associate combination medication .</brief_summary>
	<brief_title>Combined Effects Non-statin Treatments Apolipoprotein A-I Up-Regulation ( CENTAUR ) : A Feasibility Study</brief_title>
	<detailed_description>Objectives Summary * To investigate whether progressive addition fibrate niacin baseline statin therapy improve apolipoprotein A-I kinetics , postprandial lipidemia , postabsorptive lipoprotein metabolism adult men woman atherogenic dyslipidemia . Major Efficacy Aims - Objective 1 test hypothesis fibrate ABT335 extend release ( ER ) niacin progressively improve apolipoprotein A-I kinetics add sequentially baseline therapy atorvastatin . The key outcome include apolipoprotein AI rate catabolism rate production . - Objective 2 test hypothesis fibrate ABT335 ER niacin progressively improve postprandial lipidemia oral fat challenge add sequentially baseline therapy atorvastatin . Key outcomes include incremental area curve triglycerides high-density lipoprotein cholesterol . - Objective 3 test hypothesis fibrate ABT335 ER niacin progressively improve marker postabsorptive lipoprotein metabolism add sequentially baseline therapy atorvastatin . Key outcomes include a. fast cholesterol efflux , b. HDL cholesterol , apolipoprotein A-I , enzymes remodel HDL , c. atherogenic lipoprotein , d. marker energy metabolism e. marker inflammation . Additional Aims * Objective 4 ass tolerability adverse event ABT335 ER niacin add sequentially atorvastatin . Specifically , assess change hepatobiliary laboratory test ( include incidence elevation ) , incidence symptomatic myalgia , incidence flushing . On exploratory basis , enhance flush evaluation objective subjective measurement flush inpatient visit . Study Design : This open-label feasibility study fixed-sequence addition lipid-altering medication , comparison make baseline subject . Subjects begin lead-in phase start study statin ( atorvastatin ) switch previous statin therapy study statin . Subjects wash exclude lipid-altering drug lead-in . Subjects return first inpatient visit , baseline study statin monotherapy . At end visit , subject start fibrate therapy ( ABT335 ) . They repeat study dual therapy statin fibrate , add niacin ( ER niacin ) . To minimize flush chronic treatment , start aspirin 325 mg daily , titrate 325 mg take low dose aspirin ( e.g . 81 mg ) . Finally , repeat study triple therapy statin , fibrate , niacin/aspirin .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Men/women age 1880 year . 2 . Low HDLC , adjust baseline statin use 1 . Not statin : Men HDL &lt; = 40 woman HDL &lt; = 50 mg/dL 2 . On statin : Men HDL &lt; = 42 woman HDL &lt; = 52 mg/dL 3 . TG/HDL ratio &gt; = 3.5 4 . Able understand agree inform consent 5 . Women childbearing age must test negative urine pregnancy test agree use reliable birth control study 1 month last dose study drug . Reliable method include oral contraceptive , barrier method , intrauterine device , partner vasectomy , abstinence . 6 . Willing available study duration follow study procedure 1 . Subjects follow lipoprotein disorder : 1 . Patients highpotency lipidlowering regimen , define two prescription lipidaltering medication ( exclude fish oil ) one highdose statin ( 40 mg/day rosuvastatin , 80 mg/day approve statin ) . Those combination therapy low statin dose take highdose statin monotherapy ( exclude fish oil ) may participate . Patients switch atorvastatin 10 mg and/or wash lipid medication participate 2 . LDL &gt; 190 mg/dL 3 . TG &gt; 750 mg/dL pancreatitis triglyceridemia , regardless current TG level 4 . Dysbetalipoproteinemia ( VLDL/TG &gt; 0.3 AND TG &gt; 200 mg/dL ) . 2 . Use nonstatin lipid therapy prior study initiation exclusionary ( n.b . washout nonstatins permit ) : 1 . Niacin &gt; 250 mg/ day within 6 week : Advicor , Niaspan , Niacor , Simcor , SloNiacin , supplemental niacin 2 . Fibrates within 12 week : fenofibrate ( Antara , Lofibra , Tricor , Triglide ) , gemfibrozil ( Lopid ) , clofibrate 3 . Enterically active drug within 4 week : colestipol , cholestyramine , colesevelam , ezetimibe , orlistat . 4 . Red yeast rice treatment phase study ( i.e . must switch study statin ) 5 . Fish oil &gt; 2 g/day within 4 week : Lovaza ( n√©e Omacor ) , numerous supplement 6 . Altered dose selective estrogen receptor modulator ( SERM ) within 4 week 3 . Intolerance statin , fibrate , aspirin , deuterated leucine , niacin 4 . Contraindications medication , include chronic muscle disease , history rhabdomyolysis , moderatesevere gout , severe peptic ulcer disease , bleed disorder , aspirinsensitive asthma . 5 . Diabetics , fast glucose &gt; 110 mg/dL two different day screen , use antidiabetic medication within 6 week screen visit 6 . Chronic renal insufficiency , nephrotic syndrome , current serum creatinine &gt; 2.5 mg/dL , GFR &lt; 60 mL/min/1.73m2 MDRD equation . 7 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) , total bilirubin &gt; 2 X upper limit normal ( ULN ) , albumin &lt; 2.5 mg/dL , prothrombin time ( PT ) &gt; 1.5 X ULN , partial thromboplastin time ( PTT ) &gt; 1.5 X ULN , current active hepatobiliary disease 8 . Hemoglobin ( Hgb ) &lt; 10 mg/dL 9 . Weight &lt; 110 lbs 10 . Use investigational drug within 6 week prior screen visit 11 . Major surgery within previous 6 week , anticipate major surgery course study , history organ transplant 12 . Nonskin malignancy within previous 5 year 13 . Drug abuse within past 3 year , regular alcohol use &gt; 14 drinks/week 14 . Women pregnant , plan conceive , breastfeed 15 . Any serious unstable medical psychological condition , investigator 's opinion would compromise subject safety successful participation . 16 . Currently adhere , plan adhere use within 3 month prior screen , supplement intend weight loss adopt diet aggressive carbohydrate restriction , limited Atkins South Beach diet . 17 . Currently take Vitamin A supplement ( multivitamin allow ) ( washout permit ) 18 . Excluded concomitant medication 1 . Immunosuppressants within 2 month prior screen likely require treatment course study 2 . Warfarin . 19 . Disinclination dairy product ( e.g . inviolable dietary restriction lactose intolerance 8oz glass milk despite lactase supplementation ) Lactase supplementation allow study . 20 . Regular consumer grapefruit juice , currently take medication metabolize CYP 3A4 ( cyclosporine , itraconazole , ketoconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor , nefazodone ) 21 . History pancreatitis gallbladder disease 22 . History coronary heart disease 23 . History intolerance/adverse reaction heparin woman dysfunctional uterine bleed 24 . Thrombocytopenia screen 25 . History intracerebral significant GI bleed 26 . Subjects regular strenuous activity CK &gt; 3x ULN screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Low HDL cholesterol</keyword>
	<keyword>High triglyceride</keyword>
	<keyword>niacin</keyword>
	<keyword>fibrate</keyword>
</DOC>